ID: h-analogy-bb6d7fb1
Hypothesis

Closed-loop orexin receptor modulation to entrain circadian glymphatic clearance in neurodegeneration via orexin-AQP4 astrocyte coupling

Drawing from Alzheimer's disease evidence that neuromodulation restores circuit-level oscillations, we propose that targeted orexin receptor agonism (OX1R/OX2R) can entrain circadian glymphatic clearance by coupling orexinergic arousal s.
EvidencePending (0%)📖 2 cit🗣 1 debates 3 support 2 oppose
Mechanistic 0.45 (15%) Evidence 0.40 (15%) Novelty 0.75 (12%) Feasibility 0.00 (12%) Impact 0.00 (12%) Druggability 0.00 (10%) Safety 0.00 (8%) Competition 0.00 (6%) Data Avail. 0.00 (5%) Reproducible 0.00 (5%) KG Connect 0.50 (8%) 0.533 composite

🧪 Overview

Drawing from Alzheimer's disease evidence that neuromodulation restores circuit-level oscillations, we propose that targeted orexin receptor agonism (OX1R/OX2R) can entrain circadian glymphatic clearance by coupling orexinergic arousal signaling to astroglial AQP4 polarization along perivascular pathways. This approach would use a closed-loop system—tracking sleep-wake EEG signatures and delivering orexin receptor modulation during specific circadian phases—to restore the 24-hour glymphatic clearance rhythm impaired in neurodegeneration. The mechanism predicts that orexin receptor activation directly upregulates AQP4 polarization on astrocytic endfeet, enhancing convective perivascular influx.

Analogy rationale: The Alzheimer's source demonstrates that non-invasive neuromodulation can restore a physiological rhythm (gamma oscillations) lost to disease, using interneuron targeting. We extend this to the circadian-glymphatic axis in neurodegeneration, where orexin receptor modulation analogously targets a rhythm (glymphatic clearance) via neuromodulation. Both involve APP pathway dysfunction as a shared mechanistic substrate across neurodegenerative diseases.

...

🧬 Mechanism

No curated mechanism pathway recorded for this hypothesis.

⚖️ Evidence

⚖️ Evidence Matrix3 supports0 contradicts
Supports
Combined effects of HCRTR1/2 gene variants and non-genetic factors on sleep-wake transition and hemodynamic stability during propofol, dexmedetomidine, and remifentanil anesthesia.
Pharmacol Rep2025PMID:40439868
Supports
Is HCRTR2 a genetic risk factor for Alzheimer's disease?
Dement Geriatr Cogn Disord2014PMID:24969517
Supports
Absence of mutations in HCRT, HCRTR1 and HCRTR2 in patients with ROHHAD.
Respir Physiol Neurobiol2016PMID:26555080
📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — HCRTR1

No curated PDB or AlphaFold mapping for HCRTR1 yet. Search RCSB →

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for HCRTR1 →

No DepMap CRISPR Chronos data found for HCRTR1.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0004
Events (7d)
1
Price History
▲2.2%

💾 Resource Usage

No resource usage or linked notebooks recorded for this hypothesis yet.

Metadatasource: v1_phase_c_backfill · origin_type: analogy
sourcev1_phase_c_backfill
origin_typeanalogy
_schema_version1
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting 0 contradicting 0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.